Logo image of MTAL

MAC COPPER LTD (MTAL) Stock Fundamental Analysis

NYSE:MTAL - New York Stock Exchange, Inc. - JE00BQBC8469 - Common Stock - Currency: USD

9.175  -0.02 (-0.27%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MTAL. MTAL was compared to 153 industry peers in the Metals & Mining industry. MTAL may be in some trouble as it scores bad on both profitability and health. MTAL has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year MTAL has reported negative net income.
MTAL had a positive operating cash flow in the past year.
In the past 5 years MTAL reported 4 times negative net income.
In the past 5 years MTAL reported 4 times negative operating cash flow.
MTAL Yearly Net Income VS EBIT VS OCF VS FCFMTAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

MTAL has a Return On Assets of -5.80%. This is in the lower half of the industry: MTAL underperforms 63.40% of its industry peers.
With a Return On Equity value of -14.71%, MTAL is not doing good in the industry: 65.36% of the companies in the same industry are doing better.
MTAL has a Return On Invested Capital of 5.00%. This is in the better half of the industry: MTAL outperforms 64.05% of its industry peers.
Industry RankSector Rank
ROA -5.8%
ROE -14.71%
ROIC 5%
ROA(3y)-6.21%
ROA(5y)N/A
ROE(3y)-23.53%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTAL Yearly ROA, ROE, ROICMTAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

MTAL has a Operating Margin of 22.68%. This is in the better half of the industry: MTAL outperforms 78.43% of its industry peers.
MTAL has a better Gross Margin (31.07%) than 69.93% of its industry peers.
Industry RankSector Rank
OM 22.68%
PM (TTM) N/A
GM 31.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTAL Yearly Profit, Operating, Gross MarginsMTAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

2

2. Health

2.1 Basic Checks

MTAL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MTAL has more shares outstanding
The debt/assets ratio for MTAL has been reduced compared to a year ago.
MTAL Yearly Shares OutstandingMTAL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M
MTAL Yearly Total Debt VS Total AssetsMTAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 500M 1B

2.2 Solvency

MTAL has an Altman-Z score of 0.73. This is a bad value and indicates that MTAL is not financially healthy and even has some risk of bankruptcy.
MTAL's Altman-Z score of 0.73 is on the low side compared to the rest of the industry. MTAL is outperformed by 77.78% of its industry peers.
The Debt to FCF ratio of MTAL is 7.34, which is on the high side as it means it would take MTAL, 7.34 years of fcf income to pay off all of its debts.
MTAL has a Debt to FCF ratio of 7.34. This is in the better half of the industry: MTAL outperforms 66.67% of its industry peers.
MTAL has a Debt/Equity ratio of 0.63. This is a neutral value indicating MTAL is somewhat dependend on debt financing.
MTAL's Debt to Equity ratio of 0.63 is on the low side compared to the rest of the industry. MTAL is outperformed by 80.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 7.34
Altman-Z 0.73
ROIC/WACC0.44
WACC11.31%
MTAL Yearly LT Debt VS Equity VS FCFMTAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

MTAL has a Current Ratio of 1.12. This is a normal value and indicates that MTAL is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.12, MTAL is not doing good in the industry: 81.70% of the companies in the same industry are doing better.
A Quick Ratio of 0.97 indicates that MTAL may have some problems paying its short term obligations.
With a Quick ratio value of 0.97, MTAL is not doing good in the industry: 69.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.97
MTAL Yearly Current Assets VS Current LiabilitesMTAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.56% over the past year.
Looking at the last year, MTAL shows a very strong growth in Revenue. The Revenue has grown by 114.30%.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.56%
Revenue 1Y (TTM)114.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.3%

3.2 Future

Based on estimates for the next years, MTAL will show a very strong growth in Earnings Per Share. The EPS will grow by 60.97% on average per year.
The Revenue is expected to grow by 11.76% on average over the next years. This is quite good.
EPS Next Y382.14%
EPS Next 2Y170.91%
EPS Next 3Y87.64%
EPS Next 5Y60.97%
Revenue Next Year10.37%
Revenue Next 2Y14.62%
Revenue Next 3Y12.18%
Revenue Next 5Y11.76%

3.3 Evolution

MTAL Yearly Revenue VS EstimatesMTAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
MTAL Yearly EPS VS EstimatesMTAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1

5

4. Valuation

4.1 Price/Earnings Ratio

MTAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 17.08, the valuation of MTAL can be described as rather expensive.
MTAL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MTAL is cheaper than 65.36% of the companies in the same industry.
MTAL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 20.42, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 17.08
MTAL Price Earnings VS Forward Price EarningsMTAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MTAL is valued cheaply inside the industry as 83.01% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MTAL indicates a rather cheap valuation: MTAL is cheaper than 87.58% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.43
EV/EBITDA 6.43
MTAL Per share dataMTAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MTAL's earnings are expected to grow with 87.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y170.91%
EPS Next 3Y87.64%

0

5. Dividend

5.1 Amount

No dividends for MTAL!.
Industry RankSector Rank
Dividend Yield N/A

MAC COPPER LTD

NYSE:MTAL (5/7/2025, 1:12:45 PM)

9.175

-0.02 (-0.27%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-21 2025-07-21/bmo
Inst Owners41.12%
Inst Owner Change-31.34%
Ins Owners2.87%
Ins Owner ChangeN/A
Market Cap756.57M
Analysts80
Price Target14.92 (62.62%)
Short Float %3.03%
Short Ratio5.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.69%
PT rev (3m)-12.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.08
P/S 2.22
P/FCF 13.43
P/OCF 6.48
P/B 1.36
P/tB 1.36
EV/EBITDA 6.43
EPS(TTM)-0.99
EYN/A
EPS(NY)0.54
Fwd EY5.86%
FCF(TTM)0.68
FCFY7.44%
OCF(TTM)1.42
OCFY15.43%
SpS4.13
BVpS6.74
TBVpS6.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.8%
ROE -14.71%
ROCE 6.33%
ROIC 5%
ROICexc 5.82%
ROICexgc 5.82%
OM 22.68%
PM (TTM) N/A
GM 31.07%
FCFM 16.53%
ROA(3y)-6.21%
ROA(5y)N/A
ROE(3y)-23.53%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 7.34
Debt/EBITDA 2.25
Cap/Depr 77.1%
Cap/Sales 17.73%
Interest Coverage 1.64
Cash Conversion 75.01%
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.97
Altman-Z 0.73
F-Score7
WACC11.31%
ROIC/WACC0.44
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.56%
EPS Next Y382.14%
EPS Next 2Y170.91%
EPS Next 3Y87.64%
EPS Next 5Y60.97%
Revenue 1Y (TTM)114.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.3%
Revenue Next Year10.37%
Revenue Next 2Y14.62%
Revenue Next 3Y12.18%
Revenue Next 5Y11.76%
EBIT growth 1Y660.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.68%
EBIT Next 3Y48.09%
EBIT Next 5Y37.96%
FCF growth 1Y252.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1097.17%
OCF growth 3YN/A
OCF growth 5YN/A